Navigation Links
Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839

to cause long-term sensitization and irritancy. No sensitization reactions were recorded in any of the subjects, and low irritancy potential was confirmed. Additionally, in all Phase I studies no serious adverse events were observed in any study subject.

About REP8839

REP8839 is a novel topical antibacterial ointment that targets the bacterial methionyl tRNA (MetRS) enzyme. MetRS is an unexploited target in clinically-important Gram-positive bacteria and represents a promising platform for the development of new antibacterial agents with no cross-resistance to currently marketed antibiotics. In vitro, REP8839 is highly active against major skin pathogens such as Streptococcus pyogenes and Staphylococcus aureus (S. aureus), including drug-resistant strains such as MRSA, mupirocin-resistant and vancomycin-resistant S. aureus.

About Impetigo

Impetigo is a contagious skin disorder caused by bacterial infection and characterized by crusting, red skin lesions, most frequently affecting children. It is the third most common skin disease in children, causing peak incidence among those aged two to five years. Since 2004, the incidence of impetigo has increased 21 percent. In 2006, topical antibiotic prescriptions accounted for 48 percent of all impetigo treatments.

About Replidyne, Inc.

Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne's lead product, faropenem medoxomil, is a novel oral, community antibiotic, expected to be appropriate for use as a first-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne's second drug candidate, REP8839, is a topical anti-infective product candidate in development for the treatment of skin and wound infections, including methicillin-resistant S. aureus (MRSA) infections. Replidyne is also pursuing the development of other novel anti-infect
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Replidyne Phase II Pediatric Trial Meets Primary Objective
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:8/22/2014)... Aug. 22, 2014  As the Medical Affairs, role ... leaders in this area are exploring methods to develop ... Medical Affairs Consortium at Best Practices, LLC is designed ... insights about the key challenges they face. The consortium ... through three virtual roundtable discussions where leaders discuss key ...
(Date:8/22/2014)...  Dr. Mark Rasak , MD is recognized ... Award in the field of Medicine as a result ... Dr. Rasak has over 15 years of ... the business; overseeing the daily operations; interventional cardiology; complex ... addition, he is an honored Fellow of the American ...
(Date:8/22/2014)... --  Zacks Equity Research highlights Epizyme (Nasdaq: EPZM - ... (Nasdaq: PNRA - Free Report ) as the Bear of ... Therapeutics (Nasdaq: FOLD - Free Report ), Sanofi (NYSE: ... Free Report ). Here is a synopsis of all ... The biotech bull market is far from over ...
Breaking Medicine Technology:Best Practices' Medical Affairs Consortium Survey Has Achieved Strong Participation 2Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6
... Althea Technologies, Inc., a leading provider of development ... its inaugural Health and Wellness Fair today. The fair ... daily activities to promote physical and mental health amongst ... encouraged to participate in daily challenges and talks. Today,s ...
... 2011 Delcath Systems, Inc. (NASDAQ: DCTH ) ... Life Sciences Management Access Conference on Tuesday, August 16, 2011 ... Financial Officer, will provide an overview of the Company,s business ... this conference is by invitation only. Delcath will offer a ...
Cached Medicine Technology:Althea Technologies Hosts Health and Wellness Week 2Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011 2Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011 3
(Date:8/22/2014)... August 22, 2014 Today, Zane Benefits, ... guide on Account-Based Health Plans. , According to Zane ... a strategy to lower the cost of healthcare without ... medical spending accounts, however, can be confusing. , The ... learn the four main types of ABHPs. It also ...
(Date:8/22/2014)... This report studies the "Sample Preparation Market by ... Kits (Isolation, Purification), By Application (Genomics, Proteomics), by ... 2018" This market was valued at $4,254.8 million ... a CAGR of 5.9% from 2013 to 2018, ... 98 market data Tables and 23 Figures spread ...
(Date:8/22/2014)... Recently, iFitDress.com, a well-known wedding dress manufacturer and ... wedding gowns . In addition to this, the company’s ... are provided with low shipping fees. , He ... new wedding gowns. In our online store, there are ... choose from. What’s more, all of them are extremely ...
(Date:8/22/2014)... 2014 (HealthDay News) -- Many Americans know little about how ... of an outbreak in the United States, a new survey ... worried that there will be a major Ebola outbreak in ... an immediate family member will get sick with the deadly ... School of Public Health poll. However, those opinions don,t ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 Mi40x ... uses university-proven research to show people how they can use ... muscle in only a matter of weeks has caught the ... “Ben Pakulski is one of the most well-known bodybuilders in ... the body he has today, that in itself is a ...
Breaking Medicine News(10 mins):Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Discounted Wedding Gowns For Sale At Leading Online Shop iFitDress.com 2Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2
... a medical device company focused on the treatment of ... Chief,Executive Officer, and Gregory J. Tibbitts, Chief Financial Officer, ... Growth Conference in,New York, NY on Thursday, September 20, ... A live Web cast and recording of the ...
... Sept. 17 John Brooke, General Manager of,Billian,s ... speaking at Dreamforce ,07 Global Gathering, Salesforce.com,s 5th,Annual ... week. Dreamforce is the ultimate gathering of ... base of Salesforce and AppExchance,users spanning industries, roles ...
... commonly used measure for pain screening may only be modestly ... Medicine and the University of North Carolina. In a study ... General Internal Medicine, they evaluate the usefulness of a scale ... pain from 0 (no pain) to 10 (worst pain). ...
... Opening of the 62nd United Nations General Assembly Tomorrow, September ... ... people dying,of hunger every day and governments failing to meet their millennium,commitment to ... food and hunger to play a,central role "on the table" of the 62nd ...
... 17, 2007) Contrary to concerns that restricting work ... patient care or the residents education, a study in ... College of Surgeons found that limiting work hours does ... addition, the study found that the new model improved ...
... Association,Inc. ("SMART"), announced today that it has become ... a not-for-profit, multi-industry,association working to stimulate the understanding, ... The Smart Card Alliance is the sole ... on the impact and value of Smart,cards in ...
Cached Medicine News:Health News:CryoCor to Present at Maxim Group First Annual Growth Conference in New York 2Health News:Billian's HealthDATA GM Speaking on Dreamforce 07 Panel 2Health News:Rating your pain from 0 to 10 might not help your doctor 2Health News:HungerFREE Campaign Tells UN: 'Put food on the table' 2Health News:Study finds limiting work hours for surgical residents enhances training 2Health News:SMART Association Becomes 'Healthcare Council Member' of Smart Card Alliance 2
... is a monoclonal antibody based ... confirmatory identification of Neisseria gonorrhoeae. ... isolated, viable or fresh cultures. ... two minute rotation, a positive ...
Rapid Test Kit...
... The InTray™ GC is a ... detection of both Neisseria gonorrhoeae and ... a long shelf life and is ... system. Simply inoculate, incubate and ...
OneStep Strip Style Gonorrhea Test is a rapid direct binding test for the visual detection of gonorrhea antigen, in the secretory specimen and urine from urogenital system, as an aid in the diagnosis...
Medicine Products: